Imagion Biosystems Ltd has released a press release.
Non-renounceable Entitlement Offer
Filed with ASX ·
6ix hasn’t read this filing yet.
Imagion Biosystems Ltd. on 6ix
In the deck
Earlier from Imagion Biosystems
- Appendix 4E
- Company Update - Phase 1 Study Independent Review
- Positive clinical data reported at breast cancer symposium
- 2021 R&D Tax Refund
- Prostate cancer research update
Later from Imagion Biosystems
- Imagion Funding Update
- Results of Non-renounceable Entitlement Offer
- Imagion Announces New CEO
- Imagion to complete the MagSense HER2 Phase 1 Study
- Non-renounceable Entitlement Offer Shortfall
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems